U.S. markets closed

Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?

Zacks Equity Research

Coherus BioSciences, Inc. CHRS is scheduled to release fourth-quarter 2019 results on Feb 27.

The company’s earnings beat estimates in three of the trailing four quarters and missed the same in the other one. Its four-quarter surprise is positive 149.9%, on average. In the third quarter, Coherus reported a positive earnings surprise of 75%.

Shares of Coherus have increased 52.1% in the past year against the industry’s 3.5% decline.

 

Let’s see how things have shaped up for the quarter to be reported.

Factors to Note

Udenyca (pegfilgrastim-cbqv) has been a market-leading pegfilgrastim biosimilar to Neulasta (pegfilgrastim)in the United States and achieved about 19% of unit market share at the end of September 2019. We expect the drug to have performed well in the quarter.

The company expects to file a biologics license application (BLA) for CHS-1420, an anti-TNF product candidate, as an AbbVie’s (ABBV) Humira biosimilar. The company expects to incur additional investment in manufacturing activities before filing any BLA or marketing authorization applications submission. We expect the company to provide an update on its investment activity in the the fourth quarter earnings call.

The company acquired exclusive rights from Bioeq IP AG, a Swiss biopharmaceutical joint venture, to commercialize Bioeq’s Lucentis (ranibizumab) biosimilar candidate in the United States. Bioeq planned to file a BLA with the FDA in the fourth quarter and Coherus plans to launch the product in the United States in 2021. We expect an update on progress with the BLA filing in the conference call.

We also expect the company to provide an update on the license and settlement agreement with Pfizer related to patents and applications associated with Humira (adalimumab) formulations.

What Our Model Indicates

Our proven model does not conclusively predict an earnings beat for Coherus this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here, as you will see below.

Earnings ESP: Coherus has an Earnings ESP of 0.00%, as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged a profit of 68 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Coherus BioSciences, Inc. Price and EPS Surprise

Coherus BioSciences, Inc. Price and EPS Surprise

Coherus BioSciences, Inc. price-eps-surprise | Coherus BioSciences, Inc. Quote

 Stocks That Warrant a Look

Here are a few healthcare stocks worth considering, as our model shows that these have the right mix of elements to beat estimates this time around.

Vericel Corporation VCEL has an Earnings ESP of +11.29% and a Zacks Rank #1. The company is scheduled to release fourth-quarter results on Feb 25.

Sage Therapeutics Inc. SAGE has an Earnings ESP of +2.74% and a Zacks Rank #3. The company is scheduled to release fourth-quarter results on Feb 27.

AMAG Pharmaceuticals, Inc. AMAG has an Earnings ESP of +36.55% and a Zacks Rank #3.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.7% per year. These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AMAG Pharmaceuticals, Inc. (AMAG) : Free Stock Analysis Report
 
Coherus BioSciences, Inc. (CHRS) : Free Stock Analysis Report
 
Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report
 
Vericel Corporation (VCEL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research